Ma, C. (2023) “Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier?”, Canadian IBD Today. Toronto, Canada, 1(S05), pp. 2–7. doi: 10.58931/cibdt.2023.1S0510.